京颐股份KYEE品牌怎么样 申请店铺

我要投票 京颐股份KYEE在物联网行业中的票数:277 更新时间:2025-07-03
京颐股份KYEE是哪个国家的品牌?「京颐股份KYEE」是 上海京颐科技股份有限公司 旗下著名品牌。该品牌发源于上海市,由创始人李 *在2009年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力京颐股份KYEE品牌出海!将品牌入驻外推网,定制京颐股份KYEE品牌推广信息,可以显著提高京颐股份KYEE产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

京颐股份KYEE怎么样

上海京颐科技股份有限公司,是国内优良的智慧医疗技术及服务提供商,创立于2004年,为京颐集团成员企业之一,业务范围涵盖移动医疗、医院HRP、医疗物联网、护理教育、HCRM、云HIS、一卡通、医疗云等诸多领域,全面布局医疗云、数字化医院、区域智慧医疗。公司的优良团队创造了多项骄人业绩,成功为国内超过3000家各类型医疗机构提供技术、产品及服务,其中包括700家以上三级医院,帮助医疗机构提升服务质量和效率,保障医疗安全。

针对中小型医疗机构对复杂医疗信息化设施的建设需求,京颐股份以云HIS、云HRP、云PACS、云LIS、云HCRM等为核心产品,升级为云服务模式,以此为基础构建“京颐医疗云”,成为公司面向未来的核心战略。京颐医疗云通过新型运营模式,帮助中小型医疗机构实现信息化建设的低成本、免维护、高安全。

京颐股份在深耕医疗信息化13年的历程中锐意创新,采用移动互联网技术、云计算和包括SaaS在内的多种运营模式,提供面向中小型医疗机构的医疗云服务、面向医生和护理工作人员的日常业务系统、面向医院管理的系列精细化管理工具、面向医患关系的沟通管理平台、面向医疗机构的区域协同服务等,帮助医疗机构有效降低系统建设成本和运维成本,构建全新服务体系,创新医疗服务模式。

京颐股份一直把技术研发视为推动企业可持续发展的命脉,加强核心技术的竞争力,目前在上海、西安、南京等多地设立技术中心,并与上海交通大学共同成立联合研究中心,以持续推动业务创新。2016年7月,京颐股份顺利通过CMMI5最高等级评估,标志着公司在软件开发过程的能力成熟度和项目管理水平再上新台阶。

基于独特的创新经营理念、成长性、高增长潜质、核心竞争力等因素。未来,京颐股份将继续加大投入支持创新,精耕细作布局智慧医疗领域。

京颐股份始终以“创新、坚持、团队”为核心发展元素,秉持“京颐的产品及服务,帮助社会改善民生”的信念,立志成为一家受社会、股东、员工尊敬的企业,以期持续为社会及行业发展创造价值!


Shanghai Jingyi Technology Co., Ltd., founded in 2004, is an excellent domestic intelligent medical technology and service provider. It is one of the member enterprises of Jingyi group. Its business scope covers mobile medical, hospital HRP, medical Internet of things, nursing education, HCRM, cloud his, one card, medical cloud and many other fields. It has a comprehensive layout of medical cloud, digital hospital and regional intelligent medical service. The company's excellent team has created a number of remarkable achievements, and has successfully provided technology, products and services to more than 3000 domestic medical institutions of various types, including more than 700 tertiary hospitals, to help medical institutions improve service quality and efficiency, and ensure medical safety. In view of the construction requirements of small and medium-sized medical institutions for complex medical information facilities, Jingyi Co., Ltd. upgraded its core products, such as cloud his, cloud HRP, cloud PACS, cloud lis, cloud HCRM, etc., to a cloud service mode, based on which to build "Jingyi medical cloud", becoming the company's core strategy for the future. Through the new operation mode, Jingyi medical cloud helps small and medium-sized medical institutions realize the low cost, maintenance free and high security of information construction. Jingyi Co., Ltd. has been deeply engaged in medical informatization for 13 years. It adopts mobile Internet technology, cloud computing and multiple operation modes including SaaS to provide medical cloud services for small and medium-sized medical institutions, daily business systems for doctors and nursing staff, a series of fine management tools for hospital management, and communication management level for doctor-patient relationship Taiwan, regional collaborative services for medical institutions, etc., help medical institutions effectively reduce the cost of system construction and operation and maintenance costs, build a new service system, and innovate the medical service model. Jingyi has always regarded technology research and development as the lifeblood of promoting the sustainable development of enterprises and strengthening the competitiveness of core technologies. At present, it has set up technology centers in Shanghai, Xi'an, Nanjing and other places, and jointly established joint research centers with Shanghai Jiaotong University to continuously promote business innovation. In July 2016, Jingyi successfully passed the CMMI5 highest level evaluation, marking the company's capability maturity and project management level in the software development process to a new level. Based on the unique innovative business philosophy, growth, high growth potential, core competitiveness and other factors. In the future, Jingyi Co., Ltd. will continue to increase investment in support of innovation, intensive cultivation and layout of intelligent medical field. Jingyi Co., Ltd. always takes "innovation, persistence and team" as the core development element, adheres to the belief of "Jingyi's products and services to help the society improve people's livelihood", and is determined to become an enterprise respected by the society, shareholders and employees, with a view to continuously creating value for the social and industrial development!

本文链接: https://brand.waitui.com/d88faa0c7.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

医药、北交所相关产品领跑,主动权益类基金上半年平均收益6.78%

公募基金上半年交出亮眼答卷。Choice数据显示,主动权益类基金上半年平均收益为6.78%,超八成实现正收益。其中,347只基金收益在20%以上,50只收益超过40%,更有11只收益超60%。中信建投北交所精选两年定开混合基金夺得“半程冠军”,收益超80%。重仓创新药的基金业绩也较为亮眼,在主动权益类基金业绩前十强中占据六席。展望下半年,多家基金公司表示,市场结构性机会涌现,当前投资策略应更积极一些。(上证报)

2小时前

私募调研聚焦小盘成长风格,预判结构性行情主导市场

随着近期A股市场震荡上行,私募机构的调研图谱清晰折射出对结构性机会的深度挖掘。第三方机构最新监测数据显示,6月份私募机构调研A股上市公司频次高达1769次,751家私募机构调研涉足28个申万一级行业中的387只个股。其中,电子、医药生物、机械设备三大行业成为“调研主阵地”,而小市值成长股更成为机构扎堆调研的对象。展望后市,多家一线私募认为,结构性行情将主导市场,但不同机构的策略侧重则有所不同。(中证网)

2小时前

华泰证券:关注科技公司港股二次上市的投资机会

36氪获悉,华泰证券研报表示,对拟上市企业而言,二次上市可带来多元化的融资渠道,并借助港股“闪电配售”等机制提升融资效率,增强国际市场认知度,助力其全球化布局;对港股投资者而言,短期内有望把握港股与A股之间的折价套利机会,长期则将受益于恒生科技指数成分质量的显著提升,从而吸引更多国际资金入场;对A股投资者而言,这不仅意味着A股公司的投资价值得到国际认可,也为A股核心科技资产提供了新的国际估值参照,进而可能引发整体估值框架的重塑。

2小时前

“不扎堆”也能赢,基金经理练就多元配置硬实力

上半年主动权益类基金业绩排名前二十的基金大部分是主题投资选手:创新药、北交所、机器人……甚至有基金的名称看似是全市场选股,但前十大重仓股均来自单一热门赛道。与此同时,记者梳理发现,仍有不少基金经理在坚守多元布局的前提下,为投资者贡献了稳健的收益。成长派基金经理高楠管理的永赢融安和永赢睿信均在上半年取得了超过25%的回报率。通过观察两只基金的投资策略,高楠一方面参与了创新药、半导体、IT等成长性较强的科创板块,另一方面在家居、电源设备等领域进行布局。(中证网)

2小时前

6月份私募机构调研热情高涨,电子和医药生物板块受追捧

私募排排网最新统计数据显示,6月份,私募机构调研A股上市公司热情高涨。当月共有751家私募机构参与调研,覆盖28个申万一级行业中的387家上市公司,合计调研次数达到1769次,展现出机构投资者对A股市场的高度关注。从行业分布来看,电子、医药生物、机械设备、计算机等行业成为私募机构调研的重点领域。其中,电子行业以获私募机构调研275次位居榜首,涉及56家公司;医药生物行业紧随其后,获调研266次,覆盖41家公司;机械设备、计算机行业分别获得调研234次和213次,位居第三位、第四位。(证券日报)

2小时前

本页详细列出关于京颐股份KYEE的品牌信息,含品牌所属公司介绍,京颐股份KYEE所处行业的品牌地位及优势。
咨询